Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 16/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | GRK2 | P25098 | 1/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701460 | 0.97 | TTK (0.67) | TTKPIK3CBMAPK8PTK2LRRK2 | |
| SCHEMBL3142069 | 0.88 | TTK (0.54) | TTKPIK3CBMAPK8PTK2LRRK2 | |
| SCHEMBL4767742 | 0.88 | TTK (0.82) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL2956265 | 0.84 | TTK (0.71) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL3140259 | 0.83 | TTK (0.61) | TTKPIK3CBMAPK8PTK2EGFR | |
| SCHEMBL4766889 | 0.83 | TTK (0.50) | TTKPIK3CBMAPK8PTK2IGF1R | |
| SCHEMBL3708914 | 0.83 | TTK (0.56) | TTKPIK3CBMAPK8PTK2LRRK2 | |
| SCHEMBL3033327 | 0.83 | TTK (0.72) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL4768457 | 0.82 | TTK (0.52) | TTKPIK3CBMAPK8PTK2LRRK2 | |
| SCHEMBL4766915 | 0.82 | TTK (0.48) | TTKPIK3CBMAPK8PTK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | TTK 4589/4885PIK3CB 2268/4885MAPK8 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.